Latest filing published 29 Feb 2024 for Lexicon Pharmaceuticals, INC..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Kenneth B. Kassler-Taub: trading record in brief
All filings by Kenneth B. Kassler-Taub on record concern Lexicon Pharmaceuticals, Inc., in the capacity of senior executive. In total, 12 filings cover trades dated from 28 February 2022 to 28 February 2024.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 29 February 2024: an option exercise, in Lexicon Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Kenneth B. Kassler-Taub
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,087 sharesCommon StockSEC:0001127602-24-007621:0
- 18,243 sharesCommon StockSEC:0001127602-23-007925:0
- 11,297 sharesCommon StockSEC:0001127602-22-007172:0
3 of 3 declarations